Product Program year 2023 Source: CMS Open Payments

Admelog

Biological Endocrine & Metabolic Diseases

NDC 0024-5924-10

Open in the dashboard

General payments

$1,693

109 payments

Research payments

$315

1 payment

Through program year 2023, $1,693 in general payments and $315 in research payments were reported against Admelog (Endocrine & Metabolic Diseases).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2023 General $40 2
2022 General $371 22
2021 General $1,282 85
2021 Research $315 1

Breakdown

Who paid General payments · program years 2021–2023
  1. Sanofi-Aventis U.S. LLC $1,693 109 payments
Top recipients General payments · program year 2023
  1. Jonathan Chang Family Medicine · Brooklyn, NY $20 50% · 1 payment
  2. Nilar Tun New York, NY $20 50% · 1 payment

Each share is of general payments naming this product in 2023.

Specialties paid General payments · program year 2023
  1. Family Medicine $20 100% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2023
  1. New York $40 100% · 2 recipients

Each share is of general payments naming this product in 2023 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

79,064

Prescriptions dispensed, refills included

Drug cost

$15,611,959

Paid at the pharmacy, in all

Medicare Part D drugs matched to ADMELOG, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Admelog Solostar Insulin Lispro Similar name 3,068 62,526 $12,834,563
Admelog Insulin Lispro Same name 901 16,538 $2,777,396

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 189 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Robert Pearlstein Internal Medicine PA 174 $15,822 None on record
Leon Butler Internal Medicine KY 155 $13,384 None on record
Andrew Castellanos Internal Medicine OH 150 $13,337 None on record
Shaya Khabye-Hasbani Internal Medicine NY 149 $6,474 None on record
Ronald Gross General Practice NY 148 $10,578 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 189 with Patron
109 general · 1 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record